SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.Accesswire • Thursday
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB BiotherapAccesswire • Wednesday
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/13/24
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB BiotherapeuAccesswire • 09/10/24
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, IncAccesswire • 09/09/24
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeupeutics, Inc.Accesswire • 09/06/24
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingGlobeNewsWire • 09/04/24
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesGlobeNewsWire • 08/08/24
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesGlobeNewsWire • 08/05/24
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsGlobeNewsWire • 06/18/24
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsGlobeNewsWire • 05/21/24
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesGlobeNewsWire • 05/20/24
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentGlobeNewsWire • 03/25/24
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/08/24
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 01/23/24